Pay in 4 interest-free payments of $6.48 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Both are peptides that activate the same two receptors
Getting treated quickly can reduce the risk of serious complications and help you and your provider decide the safest path forward
Overdosing increases side effect risk
Long-term monitoring for pancreatitis or gallbladder issues is advised during treatment due to reported associations with GLP-1 receptor agonists
For instance, a prior study has examined the effect of a starch and sucrose reduced diet and did not find a significant change in GLP-1 (44)
FDA-approved semaglutide brands and indications Brand Ozempic (injectable) Approval date December 2017 Indication Type 2 diabetes glycemic control Brand Ozempic (injectable) Approval date January 2020 Indication Cardiovascular risk reduction in T2D Brand Rybelsus (oral tablet) Approval date September 2019 Indication Type 2 diabetes (first oral GLP-1) Brand Wegovy (injectable) Approval date June 2021 Indication Chronic weight management (BMI 30 or 27 with comorbidity) Brand Wegovy (injectable) Approval date March 2024 Indication Cardiovascular risk reduction in adults with obesity and CVD Brand Wegovy (injectable) Approval date August 2025 Indication Non-cirrhotic MASH with F2-F3 fibrosis (ESSENCE) Brand Wegovy oral 25 mg pill Approval date December 2025 Indication Chronic weight management (OASIS 4 basis) Brand Ozempic (injectable) Approval date February 2026 Indication CKD progression in T2D (FLOW basis) Research-grade lyophilized semaglutide from supplier sources is not an FDA-approved drug product and is for research use only
